Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Dallas Veterans Affairs Medical Center, Dallas, TX, USA.
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211014050. doi: 10.1177/23247096211014050.
Statins are recommended for first-line management of elevated cholesterol in the primary and secondary prevention of atherosclerotic cardiovascular disease. Statins may occasionally be associated with mild transaminase elevations but can also result in life-threatening liver injury. Atorvastatin is the most common cause of clinically significant liver injury in this drug class. We report a case of severe, asymptomatic liver injury in a hepatocellular pattern in a 71-year-old man occurring within 3 months of switching from simvastatin to high-intensity atorvastatin therapy. Hepatitis improved rapidly with cessation of atorvastatin and did not recur after resuming simvastatin.
他汀类药物被推荐作为动脉粥样硬化性心血管疾病一级和二级预防中升高胆固醇的一线治疗药物。他汀类药物偶尔可能与轻度转氨酶升高相关，但也可能导致危及生命的肝损伤。阿托伐他汀是该类药物中导致临床显著肝损伤的最常见原因。我们报告了一例 71 岁男性在换用高强度阿托伐他汀治疗 3 个月内发生严重、无症状的肝细胞性肝损伤的病例。停用阿托伐他汀后肝炎迅速改善，在重新使用辛伐他汀后未再复发。
